Imagen de Portada

Relationship between fear of progression and symptom burden, disease factors and social/family factors in patients with stage‐IV breast cancer in Shandong, China

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Qianrun Lu, Qiuyue Liu, Shu Fang, Yujin Ma, Baoxuan Zhang, Huihui Li, Lihua Song
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Cancer Medicine
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Association between anxiety, depression, and symptom burden in patients with advanced colorectal cancer: A multicenter cross‐sectional study
por: Lili Song, et al.
Publicado: (2024)

Trends and projection of burden on lung cancer and risk factors in China from 1990 to 2060
por: Baozhen He, et al.
Publicado: (2024)

Longer progression‐free survival with targeted therapy for patients with metastatic breast cancer
por: Mary Beth Nierengarten
Publicado: (2025)

Clonal hematopoiesis in patients with cancer and cancer survivors: From clonal burden to cardiovascular diseases
por: Christian H. Nenninger, et al.
Publicado: (2026)

Estimation of age of onset and progression of breast cancer by absolute risk dependent on polygenic risk score and other risk factors
por: Rikesh Bhatt, et al.
Publicado: (2024)

Erratum to “Chimeric antigen receptor–based immunotherapy in breast cancer: Recent progress in China”
Publicado: (2024)

Endocrine therapy may be warranted in patients with ER‐low, early‐stage breast cancer
por: Mary Beth Nierengarten
Publicado: (2025)

Changing trends in lung cancer disease burden between China and Australia from 1990 to 2019 and its predictions
por: Dan Zhao, et al.
Publicado: (2024)

Breast cancer staging for patients with “low‐risk” disease: Are they all the same?
por: Tori C. Nierenberg, et al.
Publicado: (2026)

Cardiovascular disease burden in patients with urological cancers: The new discipline of uro‐cardio‐oncology
por: Yi Zheng, et al.
Publicado: (2024)

Omitting surgical axillary staging for patients with breast‐conserving therapy
por: Mary Beth Nierengarten
Publicado: (2025)

Investigating the determinants of fear of cancer recurrence in patients with early‐stage non‐small cell lung cancer: Insights from a restricted cubic spline model
por: Man Liu, et al.
Publicado: (2024)

Comparison of survival outcomes for patients with Stage III vs de novo Stage IV breast cancer
por: Michael S. Lee, et al.
Publicado: (2025)

An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system
por: Leah M. Marcotte, et al.
Publicado: (2025)

Impact of clinical breast examination‐based screening program on care pathway, stage at diagnosis, nature of treatment, and overall survival among breast cancer patients in Morocco
por: Farida Selmouni, et al.
Publicado: (2024)

Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy
por: Helen M. Johnson, et al.
Publicado: (2024)

Achaete‐scute family bHLH transcription factor 2 activation promotes hepatoblastoma progression
por: Yutaka Kato, et al.
Publicado: (2024)

Gut microbiome in association with chemotherapy‐induced toxicities among patients with breast cancer
por: Sang M. Nguyen, et al.
Publicado: (2024)

Development and validation of the NCC‐BC‐A scale to assess patient‐reported outcomes for breast cancer patients in China
por: Fei Ma, et al.
Publicado: (2024)

Global burden, risk factors, and trends of non‐Hodgkin lymphoma: A worldwide analysis of cancer registries
por: Junjie Huang, et al.
Publicado: (2024)

Considerations for multidisciplinary management of synchronous primary breast cancer and primary lung cancer – Analysis of thirty‐one patients
por: Xue Chen, et al.
Publicado: (2024)

Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination
por: Julienne E. Bower, et al.
Publicado: (2025)

The landscape of chemotherapy modifications among women treated for stage I–IIIA breast cancer
por: Jenna Bhimani, et al.
Publicado: (2026)

Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer
por: Shuta Ohara, et al.
Publicado: (2024)

Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population‐based study in Italy
por: Luigino Dal Maso, et al.
Publicado: (2024)

Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study
por: Shuo Li, et al.
Publicado: (2024)

Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer
por: Jianing Cao, et al.
Publicado: (2024)

Omission of postoperative radiotherapy considered in older patients with breast cancer
por: Mary Beth Nierengarten
Publicado: (2025)

Imlunestrant significantly improves PFS for patients with advanced breast cancer
por: Mary Beth Nierengarten
Publicado: (2025)

Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors
por: Michael A. Liu, et al.
Publicado: (2025)

Patient factors and modifications to intended chemotherapy for women with Stages I–IIIA breast cancer
por: Jenna Bhimani, et al.
Publicado: (2025)

Clinical outcomes of coronavirus disease in patients with breast cancer treated with granulocyte colony‐stimulating factor following chemotherapy: Triangulation of evidence using population‐based cohort and Mendelian randomization analyses
por: Yali Wang, et al.
Publicado: (2024)

Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer
por: Maria J. Monroy‐Iglesias, et al.
Publicado: (2026)

Adding carboplatin to adjuvant chemotherapy improved survival in early‐stage triple‐negative breast cancer
por: Leah Lawrence
Publicado: (2026)

The death burden of colorectal cancer attributable to modifiable risk factors, trend analysis from 1990 to 2019 and future predictions
por: Ning Zhu, et al.
Publicado: (2024)

Identification of sequence polymorphism in the D‐loop region of mitochondrial DNA as a risk factor for breast cancer
por: Qian Nie, et al.
Publicado: (2024)

Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up
por: Jie Ju, et al.
Publicado: (2024)

Association between exposure to organophosphate flame retardants and epidermal growth factor receptor expression in lung cancer patients
por: Po‐Ju Chen, et al.
Publicado: (2024)

Sociodemographic and geographic factors impacting radiotherapy recommendation, initiation, and completion for patients with cancer
por: Jacob S. Hogan, et al.
Publicado: (2024)

Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study
por: Layla Andour, et al.
Publicado: (2025)